TY - JOUR T1 - Model-based meta-analysis to optimise <em>S. aureus</em>-targeted therapies for atopic dermatitis JF - medRxiv DO - 10.1101/2021.10.04.21264531 SP - 2021.10.04.21264531 AU - Takuya Miyano AU - Alan D Irvine AU - Reiko J Tanaka Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/10/07/2021.10.04.21264531.abstract N2 - Background Several clinical trials of Staphylococcus aureus (S. aureus)-targeted therapies for atopic dermatitis (AD) have demonstrated conflicting results regarding whether they improve AD severity scores. This study performs a model-based meta-analysis to investigate possible causes of these conflicting results and suggests how to improve the efficacies of S. aureus-targeted therapies.Methods We developed a mathematical model that describes systems-level AD pathogenesis involving interactions between S. aureus and Coagulase Negative Staphylococcus (CoNS). The model was calibrated to reproduce time course data of S. aureus levels, EASI scores, and EASI-75 in response to dupilumab, S. hominis A9 (ShA9) and flucloxacillin from published clinical trials. We simulated efficacies of hypothetical S. aureus-targeted therapies on virtual patients using the model.Results Our model simulation reproduced the clinically observed detrimental effects that application of ShA9 and flucloxacillin had on AD severity and showed that these effects disappeared if the bactericidal activity against CoNS was removed. A hypothetical (modelled) eradication of S. aureus by 3.0 log10 CFU/cm2, without killing CoNS, achieved comparable EASI-75 to dupilumab. This efficacy was potentiated if dupilumab was administered in conjunction with S. aureus eradication (EASI-75 at week 16; S. aureus eradication: 66.7%, dupilumab 61.6% and combination: 87.8%). The improved efficacy was also seen for virtual dupilumab poor responders.Conclusion Our model simulation suggests that killing CoNS worsens AD severity and that S. aureus-specific eradication without killing CoNS could be effective for AD patients, including dupilumab poor responders. This study will contribute to design promising S. aureus-targeted therapy.Competing Interest StatementTakuya Miyano reports personal fees from DAIICHI SANKYO CO., LTD., during the conduct of the study, outside the submitted work; Alan D Irvine reports personal fees from Sanofi Regeneron, personal fees from AbbVie, personal fees from Eli Lilly, personal fees from Pfizer, personal fees from UCB Pharma, personal fees from Novartis, personal fees from Dermavant, personal fees from Benevolent AI, personal fees from Menlo Therapeutics, personal fees from Chugai, personal fees from LEO Pharma, personal fees from Arena, during the conduct of the study; Reiko J Tanaka reports grants from British Skin Foundation, during the conduct of the study.Funding StatementThis work was funded by the British Skin Foundation (005/R/18).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:There is no relevant ethical guidelines, IRB and/or ethics committee.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe code of the QSP model is available at https://github.com/Tanaka-Group/AD_QSP_model. https://github.com/Tanaka-Group/AD_QSP_model ER -